Cargando…
Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature
The requirement of an undisrupted cold chain during vaccine distribution is a major economic and logistical challenge limiting global vaccine access. Modular, nanoparticle-based platforms are expected to play an increasingly important role in the development of the next-generation vaccines. However,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229831/ https://www.ncbi.nlm.nih.gov/pubmed/35745873 http://dx.doi.org/10.3390/pharmaceutics14061301 |
_version_ | 1784734852354932736 |
---|---|
author | Aves, Kara-Lee Janitzek, Christoph M. Fougeroux, Cyrielle E. Theander, Thor G. Sander, Adam F. |
author_facet | Aves, Kara-Lee Janitzek, Christoph M. Fougeroux, Cyrielle E. Theander, Thor G. Sander, Adam F. |
author_sort | Aves, Kara-Lee |
collection | PubMed |
description | The requirement of an undisrupted cold chain during vaccine distribution is a major economic and logistical challenge limiting global vaccine access. Modular, nanoparticle-based platforms are expected to play an increasingly important role in the development of the next-generation vaccines. However, as with most vaccines, they are dependent on the cold chain in order to maintain stability and efficacy. Therefore, there is a pressing need to develop thermostable formulations that can be stored at ambient temperature for extended periods without the loss of vaccine efficacy. Here, we investigate the compatibility of the Tag/Catcher AP205 capsid virus-like particle (cVLP) vaccine platform with the freeze-drying process. Tag/Catcher cVLPs can be freeze-dried under diverse buffer and excipient conditions while maintaining their original biophysical properties. Additionally, we show that for two model cVLP vaccines, including a clinically tested SARS-CoV-2 vaccine, freeze-drying results in a product that once reconstituted retains the structural integrity and immunogenicity of the original material, even following storage under accelerated heat stress conditions. Furthermore, the freeze-dried SARS-CoV-2 cVLP vaccine is stable for up to 6 months at ambient temperature. Our study offers a potential solution to overcome the current limitations associated with the cold chain and may help minimize the need for low-temperature storage. |
format | Online Article Text |
id | pubmed-9229831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92298312022-06-25 Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature Aves, Kara-Lee Janitzek, Christoph M. Fougeroux, Cyrielle E. Theander, Thor G. Sander, Adam F. Pharmaceutics Article The requirement of an undisrupted cold chain during vaccine distribution is a major economic and logistical challenge limiting global vaccine access. Modular, nanoparticle-based platforms are expected to play an increasingly important role in the development of the next-generation vaccines. However, as with most vaccines, they are dependent on the cold chain in order to maintain stability and efficacy. Therefore, there is a pressing need to develop thermostable formulations that can be stored at ambient temperature for extended periods without the loss of vaccine efficacy. Here, we investigate the compatibility of the Tag/Catcher AP205 capsid virus-like particle (cVLP) vaccine platform with the freeze-drying process. Tag/Catcher cVLPs can be freeze-dried under diverse buffer and excipient conditions while maintaining their original biophysical properties. Additionally, we show that for two model cVLP vaccines, including a clinically tested SARS-CoV-2 vaccine, freeze-drying results in a product that once reconstituted retains the structural integrity and immunogenicity of the original material, even following storage under accelerated heat stress conditions. Furthermore, the freeze-dried SARS-CoV-2 cVLP vaccine is stable for up to 6 months at ambient temperature. Our study offers a potential solution to overcome the current limitations associated with the cold chain and may help minimize the need for low-temperature storage. MDPI 2022-06-18 /pmc/articles/PMC9229831/ /pubmed/35745873 http://dx.doi.org/10.3390/pharmaceutics14061301 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Aves, Kara-Lee Janitzek, Christoph M. Fougeroux, Cyrielle E. Theander, Thor G. Sander, Adam F. Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title | Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title_full | Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title_fullStr | Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title_full_unstemmed | Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title_short | Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature |
title_sort | freeze-drying of a capsid virus-like particle-based platform allows stable storage of vaccines at ambient temperature |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229831/ https://www.ncbi.nlm.nih.gov/pubmed/35745873 http://dx.doi.org/10.3390/pharmaceutics14061301 |
work_keys_str_mv | AT aveskaralee freezedryingofacapsidviruslikeparticlebasedplatformallowsstablestorageofvaccinesatambienttemperature AT janitzekchristophm freezedryingofacapsidviruslikeparticlebasedplatformallowsstablestorageofvaccinesatambienttemperature AT fougerouxcyriellee freezedryingofacapsidviruslikeparticlebasedplatformallowsstablestorageofvaccinesatambienttemperature AT theanderthorg freezedryingofacapsidviruslikeparticlebasedplatformallowsstablestorageofvaccinesatambienttemperature AT sanderadamf freezedryingofacapsidviruslikeparticlebasedplatformallowsstablestorageofvaccinesatambienttemperature |